|Bid||1.120 x 4400|
|Ask||1.130 x 300|
|Day's Range||1.090 - 1.130|
|52 Week Range||1.030 - 4.020|
|PE Ratio (TTM)||-2.06|
|Earnings Date||Sep 11, 2017 - Sep 15, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||9.17|
WATERTOWN, Mass., Aug. 01, 2017-- pSivida Corp., a leader in the development of ocular sustained release drug products and technologies for eye diseases, today announced that Nancy Lurker, President and ...
WATERTOWN, Mass., July 18, 2017-- pSivida Corp., a leader in the development of sustained release drug products and technologies, today announced that three abstracts supporting the Company’ s Durasert™ ...
Converts existing ILUVIEN profit share arrangement to royalty agreement No upfront cash payment Alimera Sciences plans to file ILUVIEN for posterior uveitis indication in 17 EU countries within 8 months ...